#529: Addressing Popular Claims About Cholesterol, Dietary Fat and Heart Disease

Listen Here:

Click or simply search “Sigma Nutrition” on your podcast platform of choice.

Or listen directly on the Sigma website here.

Introduction

In episode 529 of Sigma Nutrition Radio, we discuss all things related to cholesterol, atherosclerosis, heart disease, and dietary fat. The discussion extensively covers the impact of LDL cholesterol and ApoB on atherosclerotic plaque progression, cardiovascular events, and the benefits of early LDL lowering interventions, particularly through the use of PCSK9 inhibitors alongside statins.

We address misconceptions prevalent in the low-carb and carnivore communities, dissect claims regarding saturated fats, and elucidate why atherosclerosis predominantly affects arteries and not veins. The episode sheds light on the nuanced mechanisms of cholesterol metabolism, the significance of different lipid particles, and the limited dietary impact on LP(a) levels.

Comprehensive evidence-based insights and practical recommendations for dietary patterns and cardiovascular health interventions are provided, offering clarity on these complex topics.

Note: This discussion is hosted by Simon Hill, and originally appeared as an episode of The Proof podcast.

Related resources

Join the Sigma newsletter for free
Subscribe to Sigma Nutrition Premium
Become a member of Alan Flanagan’s Alinea Nutrition Education Hub

Overview

[07:19]Understanding Cholesterol and Lipoproteins
[14:35]The Role of ApoB in Cardiovascular Risk
[25:10]Atherogenic Lipoproteins and Their Impact
[37:42]Causal Pathways and Biomarkers in Heart Disease
[47:02]Understanding Residual Risk and Triglycerides
[49:46]Paul Saladino’s Claims on LDL and Metabolic Health
[01:03:01]Addressing Concerns About Lowering Cholesterol
[01:16:16]The Importance of Early Intervention in Cholesterol Management
[01:23:36]The Future of Cholesterol Management and Gene Editing
[01:28:24]Atherosclerosis in Arteries vs. Veins
[01:36:08]Dietary Interventions to Lower ApoB Levels
[01:47:55]Modifying Keto Diet for Better Health Outcomes
[01:56:33]Plant-Based Diets and Fat Consumption
[02:05:10]Understanding Lp(a) and Its Impact on Health

Hosts

The Hosts

Click through to your app of choice to listen and subscribe:

Dr. Alan Flanagan has a PhD in nutrition from the University of Surrey, where his doctoral research focused on circadian rhythms, feeding, and chrononutrition.

This work was based on human intervention trials. He also has a Masters in Nutritional Medicine from the same institution.

Dr. Flanagan is a regular co-host of Sigma Nutrition Radio. He also produces written content for Sigma Nutrition, as part of his role as Research Communication Officer.

Dr. Alan Flanagan

a PhD in nutrition from the University of Surrey

Danny Lennon has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, and he is the founder of Sigma Nutrition.

Danny is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.

Danny Lennon

MSc. in Nutritional Sciences from University College Cork

Introduction to this Episode

Understanding the intricate relationship between cholesterol, dietary fat, and heart disease is pivotal for healthcare professionals aiming to improve cardiovascular health outcomes. With conflicting information and widespread myths, understanding these topics can be overwhelming. Thatʼs why this episode aims to shed light on these complex issues and provide you with the knowledge you need to make informed decisions about your cardiovascular health.

O en painted as the villain in the story of heart disease, cholesterol is actually a vital component for cell membrane structure, hormone production, and fat digestion. These study notes delve into the different types of cholesterol and their impact on health, and clarifies the roles of various lipoproteins, such as HDL and LDL, in transporting cholesterol through the bloodstream. Understanding the difference between these lipoproteins is essential for comprehending how cholesterol contributes to plaque formation in the arteries, leading to atherosclerosis and heart disease.

Moreover, the conversation includes strategies to manage cholesterol levels through diet, lifestyle changes, and, when necessary, medication. Our experts dispel common myths, highlight the types of fats that are essential for a balanced diet and overall health and provide practical advice on how to incorporate healthy fats into your meals without increasing your risk of heart disease.

Finally, we touch on the emerging importance of Apolipoprotein B (ApoB) as a predictor of cardiovascular risk, the clinical implications of this new understanding and how it can lead to better prevention and treatment strategies.

Useful Terminology for this Episode

Key Terms & Acronyms

Atherogenic Profile: A set of characteristics or factors that indicate a higher risk of atherosclerosis.
Chylomicrons: Large lipoprotein particles that transport dietary triglycerides and cholesterol from the intestines to other tissues a er a meal.
Endothelium: The thin layer of cells lining the interior surface of blood vessels, playing a crucial role in vascular health and the development of atherosclerosis.
Foam Cells: Lipid-laden macrophages found in atherosclerotic plaques, formed when macrophages engulf oxidized LDL particles.
Transcytosis: The process by which lipoproteins penetrate the arterial walls, contributing to the formation of atherosclerotic plaques.
Dyslipidemia: An abnormal amount of lipids (e.g., cholesterol and triglycerides) in the blood, o en linked to an increased risk of cardiovascular diseases.
Metabolic Syndrome: A cluster of conditions (including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels) that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes.
Statins: A class of drugs used to lower cholesterol levels in the blood, primarily by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol synthesis in the liver.
C-Reactive Protein (CRP): A marker of inflammation in the body that can indicate increased cardiovascular risk when elevated.
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): An enzyme that regulates the number of LDL receptors on the liver’s surface, affecting cholesterol levels in the blood. PCSK9 inhibitors are used to lower LDL cholesterol levels.

Premium Content

You are currently not signed-in as a Premium subscriber.

To view our Premium content, please log-in to your account or subscribe to Premium.